Compare AXR & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | XGN |
|---|---|---|
| Founded | 1961 | 2002 |
| Country | United States | United States |
| Employees | N/A | 209 |
| Industry | Homebuilding | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.3M | 138.0M |
| IPO Year | N/A | 2019 |
| Metric | AXR | XGN |
|---|---|---|
| Price | $19.24 | $6.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 9.3K | ★ 320.4K |
| Earning Date | 12-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | $45,947,000.00 | ★ $63,599,000.00 |
| Revenue This Year | $28.57 | $21.76 |
| Revenue Next Year | N/A | $15.63 |
| P/E Ratio | $9.72 | ★ N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $17.60 | $2.67 |
| 52 Week High | $34.00 | $12.23 |
| Indicator | AXR | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 29.08 |
| Support Level | $18.80 | $5.74 |
| Resistance Level | $19.44 | $6.21 |
| Average True Range (ATR) | 0.60 | 0.33 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 35.93 | 23.26 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.